Katie J Ewer
Overview
Explore the profile of Katie J Ewer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
9501
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanderson J, Aboagye J, Makinson R, Rapi K, Provstgaard-Morys S, Stockdale L, et al.
EBioMedicine
. 2025 Feb;
113:105570.
PMID: 39922068
Background: Crohn's Disease (CD) is a chronic, debilitating condition hypothesised to be associated with Mycobacterium avium ssp paratuberculosis (MAP) infection. It is the causative pathogen of the granulomatous inflammatory enteritis...
2.
Venkatraman N, Tiono A, Bowyer G, Bellamy D, Stockdale L, Powlson J, et al.
Lancet Microbe
. 2025 Jan;
6(3):100868.
PMID: 39805302
Background: Malaria remains a substantial public health burden among young children in sub-Saharan Africa and a highly efficacious vaccine eliciting a durable immune response would be a useful tool for...
3.
Venkatraman N, Silman D, Bellamy D, Stockdale L, Bowyer G, Edwards N, et al.
Lancet Microbe
. 2025 Jan;
6(3):100867.
PMID: 39805301
Background: R21 is a novel malaria vaccine, composed of a fusion protein of the malaria circumsporozoite protein and hepatitis B surface antigen. Following favourable safety and immunogenicity in a phase...
4.
Sang S, Datoo M, Otieno E, Muiruri C, Bellamy D, Gathuri E, et al.
Wellcome Open Res
. 2024 May;
8:450.
PMID: 38813551
Background: Falciparum malaria remains a global health problem. Two vaccines, based on the circumsporozoite antigen, are available. RTS, S/AS01 was recommended for use in 2021 following the advice of the...
5.
Schmit N, Topazian H, Natama H, Bellamy D, Traore O, Some M, et al.
Lancet Infect Dis
. 2024 Feb;
24(5):465-475.
PMID: 38342107
Background: The R21/Matrix-M vaccine has demonstrated high efficacy against Plasmodium falciparum clinical malaria in children in sub-Saharan Africa. Using trial data, we aimed to estimate the public health impact and...
6.
Datoo M, Dicko A, Tinto H, Ouedraogo J, Hamaluba M, Olotu A, et al.
Lancet
. 2024 Feb;
403(10426):533-544.
PMID: 38310910
Background: Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso. Here, we...
7.
Mugo R, Orindi B, Shee F, Bellamy D, Mwacharo J, Ewer K, et al.
PLoS One
. 2023 May;
18(5):e0286117.
PMID: 37220123
Background: RTS,S/AS01 induced anti-circumsporozoite protein (CSP) IgG antibodies are associated with the vaccine efficacy. There is currently no international standardisation of the assays used in the measurement of anti-CSP IgG...
8.
Jenkin D, Wright D, Folegatti P, Platt A, Poulton I, Alison Lawrie , et al.
Lancet Infect Dis
. 2023 Apr;
23(8):956-964.
PMID: 37060917
Background: Rift Valley fever is a viral epidemic illness prevalent in Africa that can be fatal or result in debilitating sequelae in humans. No vaccines are available for human use....
9.
Li K, Dodds M, Spreng R, Abraha M, Huntwork R, Dahora L, et al.
Front Immunol
. 2023 Mar;
14:1049673.
PMID: 36875126
Diversity in specificity of polyclonal antibody (pAb) responses is extensively investigated in vaccine efficacy or immunological evaluations, but the heterogeneity in antibody avidity is rarely probed as convenient tools are...
10.
Voysey M, Flaxman A, Aboagye J, Aley P, Belij-Rammerstorfer S, Bibi S, et al.
Clin Exp Immunol
. 2023 Feb;
211(3):280-287.
PMID: 36729167
The trajectory of immune responses following the primary dose series determines the decline in vaccine effectiveness over time. Here we report on maintenance of immune responses during the year following...